Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Next Previous
X
Search
Trial Profile

A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2018 Results assessing efficacy of cabozantinib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer published in the Gynecologic Oncology
    • 12 Oct 2017 Planned primary completion date changed from 15 Aug 2016 to 1 Oct 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top